A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial with an Open-label Run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
Latest Information Update: 10 Mar 2025
At a glance
- Drugs VLA-1601 (Primary) ; CpG 1018; Telratolimod
- Indications Zika virus infection
- Focus Adverse reactions
- Sponsors Valneva
Most Recent Events
- 06 Mar 2025 Planned End Date changed from 28 Dec 2026 to 27 Apr 2026.
- 06 Mar 2025 Planned primary completion date changed from 31 Jul 2025 to 2 May 2025.
- 06 Mar 2025 Status changed from recruiting to active, no longer recruiting.